Aygestin Taper for Heavy Bleeding in a 52-Year-Old Woman
For acute heavy bleeding in a 52-year-old woman, initiate norethisterone acetate (Aygestin) 5 mg three times daily for 10–20 days to control bleeding, then transition to a standard cyclic regimen (5–10 mg daily from day 5–25 of the cycle) for ongoing management. 1, 2, 3
Acute Management Phase (Days 1–20)
- Start norethisterone acetate 5 mg three times daily (15 mg total daily dose) for 10–20 days to achieve rapid hemostasis in heavy bleeding episodes 2, 3
- This high-dose regimen effectively controls acute bleeding by stabilizing and inducing organized shedding of the endometrium 3
- Rule out pregnancy, structural lesions (polyps, fibroids), thyroid disorders, and bleeding disorders before initiating treatment 1, 4
- Consider adding NSAIDs (e.g., ibuprofen 400–600 mg three times daily) for 5–7 days during the acute phase to further reduce blood flow 2, 4
Transition to Maintenance Therapy
- After bleeding is controlled (typically 10–20 days), transition to a cyclic maintenance regimen of norethisterone acetate 5–10 mg daily from day 5–25 of each menstrual cycle 3
- This cyclic approach reduces menstrual blood loss by approximately 53% and changes the bleeding pattern to more predictable withdrawal bleeding 5, 3
- Continue the maintenance regimen for at least 3–6 months to assess therapeutic response 5, 3
Important Considerations for Perimenopausal Women
- At age 52, this patient is likely perimenopausal, which increases the importance of excluding endometrial pathology before starting progestin therapy 6, 1
- If bleeding is unexplained or suspicious for serious pathology, defer treatment until endometrial sampling or imaging is completed 6, 4
- Norethisterone acetate is particularly appropriate in this age group as it avoids estrogen-related thrombotic risks that are elevated in women over 50 7, 6
Alternative and Adjunctive Options
- If norethisterone acetate alone is insufficient, consider adding tranexamic acid 1300 mg three times daily during menses for additional hemostatic effect 5
- A levonorgestrel-releasing IUD (LNG-IUD) is more effective than oral norethisterone (85.8% vs 53.1% reduction in menstrual blood loss) and should be considered if oral therapy fails or for long-term management 5
- For women with contraindications to hormonal therapy or treatment failure, refer for endometrial ablation or hysterectomy 1
Monitoring and Follow-Up
- No routine follow-up visit is required, but patients should return for persistent bleeding beyond 3–6 months, concerning side effects, or if bleeding recurs after initial control 2, 4
- Monitor hemoglobin and iron stores if bleeding was severe enough to cause anemia 5
- Reassess at 3–6 months to determine if continued therapy is needed or if transition to alternative management (IUD, ablation, or observation as menopause approaches) is appropriate 5
Common Pitfalls to Avoid
- Do not use norethisterone acetate as contraception during the taper—it should not be relied upon for pregnancy prevention unless used continuously 1
- Avoid copper IUDs in this setting, as they can worsen menstrual bleeding 1
- Do not continue high-dose norethisterone (15 mg/day) beyond 20 days without transitioning to a cyclic regimen, as prolonged continuous high-dose progestin increases the risk of breakthrough bleeding 1, 2